These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22310339)

  • 1. Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option.
    Schöffski P; Cerbone L; Wolter P; De Wever I; Samson I; Dumez H; Clement P; Wildiers H; Stas M
    Onkologie; 2012; 35(1-2):14-7. PubMed ID: 22310339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
    Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
    Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
    Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
    Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial.
    Bui-Nguyen B; Butrynski JE; Penel N; Blay JY; Isambert N; Milhem M; Kerst JM; Reyners AK; Litière S; Marréaud S; Collin F; van der Graaf WT;
    Eur J Cancer; 2015 Jul; 51(10):1312-20. PubMed ID: 25912752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
    Le Cesne A; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: a multicentric Italian experience.
    Martella F; Salutari V; Marchetti C; Pisano C; Di Napoli M; Pietta F; Centineo D; Caringella AM; Musella A; Fioretto L
    Anticancer Drugs; 2015 Oct; 26(9):990-4. PubMed ID: 26241804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.
    Angarita FA; Cannell AJ; Abdul Razak AR; Dickson BC; Blackstein ME
    BMC Cancer; 2016 Jan; 16():30. PubMed ID: 26786213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.
    Kawai A; Araki N; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Tanase T; Hasegawa T; Takahashi S
    Lancet Oncol; 2015 Apr; 16(4):406-16. PubMed ID: 25795406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
    Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
    Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
    Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
    Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
    Fayette J; Boyle H; Chabaud S; Favier B; Engel C; Cassier P; Thiesse P; Méeus P; Sunyach MP; Vaz G; Ray-Coquard I; Ranchère D; Decouvelaere AV; Alberti L; Pérol D; Blay JY
    Anticancer Drugs; 2010 Jan; 21(1):113-9. PubMed ID: 19887935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
    Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
    Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.
    Khalifa J; Ouali M; Chaltiel L; Le Guellec S; Le Cesne A; Blay JY; Cousin P; Chaigneau L; Bompas E; Piperno-Neumann S; Bui-Nguyen B; Rios M; Delord JP; Penel N; Chevreau C
    BMC Cancer; 2015 Oct; 15():700. PubMed ID: 26472661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
    Paz-Ares L; López-Pousa A; Poveda A; Balañá C; Ciruelos E; Bellmunt J; del Muro JG; Provencio M; Casado A; Rivera-Herrero F; Izquierdo MA; Nieto A; Tanović A; Cortes-Funes H; Buesa JM
    Invest New Drugs; 2012 Apr; 30(2):729-40. PubMed ID: 20960029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
    Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
    Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.
    Ueda T; Kakunaga S; Ando M; Yonemori K; Sugiura H; Yamada K; Kawai A
    Invest New Drugs; 2014 Aug; 32(4):691-9. PubMed ID: 24696229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
    Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A
    Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
    Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
    Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
    Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
    Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.